Overview

Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease

Status:
Recruiting

Trial end date:
2022-06-15

Target enrollment:

Participant gender:

Summary

This study evaluates the efficacy and safety of Edoxaban with the combination of edoxaban and antiplatelet in patients with stable CAD (coronary artery stenosis ≥50% on medical treatment or revascularized stable CAD [≥ 12 months for acute coronary syndrome and ≥ 6 months after stable CAD]) and high-risk atrial fibrillation (CHA2DS2-VASc score ≥2).

Phase:

Phase 4

Details

Lead Sponsor:

Gi-Byoung Nam

Collaborator:

CardioVascular Research Foundation, Korea

Treatments:

Edoxaban
Platelet Aggregation Inhibitors